Idiopathic Pulmonary Fibrosis

Latest News

Drug prolongs IPF life expectancy: Study

April 10th 2017

Two recent studies demonstrate that pirfenidone (Esbriet, Genentech) prolongs life expectancy by 2.47 years for IPF patients and that Esbriet and nintedanib (Ofev, Boehringer Ingelheim) reduce the decline in lung function.

How to help IPF patients – from their point of view

December 18th 2015

IPF drug to be tested with add-on therapy

December 14th 2015

Manufacturer-Foundation partnership to increase PF research

December 7th 2015

Top 5 findings about IPF patients

November 20th 2015

More News

© 2024 MJH Life Sciences

All rights reserved.